EPISODE · Mar 12, 2026 · 3 MIN
Faron Pharmaceuticals CEO on €40M raise for key bexmarilimab trial
from Proactive - Interviews for investors · host Proactive Investors
Faron Pharmaceuticals Limited (AIM:FARN) CEO Dr Juho Jalkanen talked with Proactive's Stephen Gunnion about the company’s planned €40 million rights offering and the next development stage for its lead immunotherapy candidate, bexmarilimab. Jalkanen explained that the planned capital raise comes at what he described as a pivotal stage for the company. The AIM and Nasdaq-listed Finnish biotech has completed an open-label phase I/II trial evaluating bexmarilimab in patients with higher-risk myelodysplastic syndromes (MDS), which produced encouraging results. The company is now preparing to advance the program into a blinded, randomised phase II trial, considered the gold standard in pharmaceutical development. Jalkanen highlighted that the main goal of the upcoming study is to measure complete remission rates among patients receiving the treatment. He explained that the key milestone will arrive relatively quickly once patients are enrolled. As he noted, “the absolute key and primary goal of the study is the complete remission rate readout… usually comes after three or so months after patients have gone on the drug.” The CEO also emphasised the broader potential of bexmarilimab beyond MDS. According to Jalkanen, strong data from the earlier trial has generated significant interest among physicians, who are now initiating investigator-led studies exploring the therapy across multiple cancer types and in combination treatments. Funding from the proposed raise is expected to extend Faron Pharmaceuticals’ cash runway into late 2027, supporting the randomised phase II study while additional investigator-initiated trials generate data in the meantime. Jalkanen said this approach should create a steady flow of clinical updates for investors as the program progresses. For more interviews and market insights, visit the Proactive YouTube channel, like this video, subscribe to the channel, and enable notifications so you never miss future updates. #FaronPharmaceuticals #Bexmarilimab #BiotechInvesting #CancerResearch #Immunotherapy #MDS #ClinicalTrials #BiotechStocks #HealthcareInnovation #AIMStocks
What this episode covers
Faron Pharmaceuticals Limited (AIM:FARN) CEO Dr Juho Jalkanen talked with Proactive's Stephen Gunnion about the company’s planned €40 million rights offering and the next development stage for its lead immunotherapy candidate, bexmarilimab. Jalkanen explained that the planned capital raise comes at what he described as a pivotal stage for the company. The AIM and Nasdaq-listed Finnish biotech has completed an open-label phase I/II trial evaluating bexmarilimab in patients with higher-risk myelodysplastic syndromes (MDS), which produced encouraging results. The company is now preparing to advance the program into a blinded, randomised phase II trial, considered the gold standard in pharmaceutical development. Jalkanen highlighted that the main goal of the upcoming study is to measure complete remission rates among patients receiving the treatment. He explained that the key milestone will arrive relatively quickly once patients are enrolled. As he noted, “the absolute key and primary goal of the study is the complete remission rate readout… usually comes after three or so months after patients have gone on the drug.” The CEO also emphasised the broader potential of bexmarilimab beyond MDS. According to Jalkanen, strong data from the earlier trial has generated significant interest among physicians, who are now initiating investigator-led studies exploring the therapy across multiple cancer types and in combination treatments. Funding from the proposed raise is expected to extend Faron Pharmaceuticals’ cash runway into late 2027, supporting the randomised phase II study while additional investigator-initiated trials generate data in the meantime. Jalkanen said this approach should create a steady flow of clinical updates for investors as the program progresses. For more interviews and market insights, visit the Proactive YouTube channel, like this video, subscribe to the channel, and enable notifications so you never miss future updates. #FaronPharmaceuticals #Bexmarilimab #BiotechInvesting #CancerResearch #Immunotherapy #MDS #ClinicalTrials #BiotechStocks #HealthcareInnovation #AIMStocks
NOW PLAYING
Faron Pharmaceuticals CEO on €40M raise for key bexmarilimab trial
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.